Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PKC sigma inhibitor
- Development stage
- Preclinical
- Lead developer
- Phoenicia BioSciences
- Modality
- Small Molecules
01
Overview
PKC sigma inhibitors are small-molecule therapeutics designed to disrupt the p21Ras signaling pathway in malignancies characterized by activating RAS mutations. By targeting Protein Kinase C sigma (PKCσ), these agents aim to inhibit the oncogenic signaling cascades that drive tumor growth and survival in RAS-mutant cancers. The program was originally developed by Phoenicia BioSciences and subsequently licensed to Viacell for further development. It is currently in the preclinical stage of development, focusing on malignancies with activating Ras mutations.
- Other names
- PKCσ inhibitorsPKC sigma inhibitorsPKCσ inhibitors (RAS-targeted)
02
Targets
PRKCD (Protein kinase C delta)
Beyond the preview
Go deeper on PKC sigma inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PKC sigma inhibitor.